Evidence map›Paper›PMID 40214869›Full record

ArticleCEN case reports2025

Renoprotective effects of combination therapy with tolvaptan and dapagliflozin in autosomal dominant polycystic kidney disease: a four-case series.

Junji Nishida, Mayuko Yamakawa, Shoko Miura, Masashi Yasutomi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CEN case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Junji NishidaDepartment of Nephrology, Kuwana City Medical Center, Kuwana, Japan. j.nishida@kuwanacmc.or.jp.ORCID 0009-0006-0876-3311
Mayuko YamakawaDepartment of Nephrology, Kuwana City Medical Center, Kuwana, Japan.
Shoko MiuraDepartment of Nephrology, Kuwana City Medical Center, Kuwana, Japan.
Masashi YasutomiDepartment of Nephrology, Kuwana City Medical Center, Kuwana, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), the most prevalent inherited kidney disorder, progresses inexorably to end-stage kidney disease (ESKD) with the vasopressin V2-receptor antagonist tolvaptan serving as a primary treatment option since 2014. While dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, was approved for treating chronic kidney disease in August 2021, its renoprotective effects in ADPKD remain uncertain due to potential vasopressin stimulation. We evaluated four Japanese ADPKD patients receiving combination therapy with tolvaptan and dapagliflozin for over two years. A 74-year-old woman (Mayo Class 1D, CKD stage 4) showed improved estimated glomerular filtration rate (eGFR) decline from - 1.39 to - 0.66 mL/min/1.73 m

Indexed as

Benzhydryl CompoundsGlucosidesPolycystic Kidney, Autosomal DominantSodium-Glucose Transporter 2 InhibitorsTolvaptanAdultAgedAntidiuretic Hormone Receptor AntagonistsDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansKidneyMaleMiddle AgedRenal Insufficiency, ChronicAntidiuretic Hormone Receptor AntagonistsBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsTolvaptanAutosomal dominant polycystic kidney diseaseEstimated glomerular filtration rate declineHeight-adjusted total kidney volumeSodium-glucose cotransporter-2 inhibitorVasopressin V2-Receptor antagonist

Identifiers

PMID40214869
PMCPMC12126371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.